1092540-52-7
1092540-52-7
Chemical Structure
Atazanavir-d18
Synonym(s): BMS-232632-d18
- CAS No.: 1092540-52-7
- Formula:C38H34D18N6O7
- Molecular Weight:722.97
IUPAC Name: methyl ((5S,10S,11S,14S)-11-benzyl-10-hydroxy-15,15-bis(methyl-d3)-5-(2-(methyl-d3)propan-2-yl-1,1,1,3,3,3-d6)-3,6,13-trioxo-8-(4-(pyridin-2-yl)benzyl)-2-oxa-4,7,8,12-tetraazahexadecan-14-yl-16,16,16-d3)carbamate
InChIKey: AXRYRYVKAWYZBR-AAPVVJSESA-N
SMILES: COC(N[C@@H](C(C([2H])([2H])[2H])(C([2H])([2H])[2H])C([2H])([2H])[2H])C(N[C@@H](CC1=CC=CC=C1)[C@@H](O)CN(NC([C@H](C(C([2H])([2H])[2H])(C([2H])([2H])[2H])C([2H])([2H])[2H])NC(OC)=O)=O)CC2=CC=C(C3=CC=CC=N3)C=C2)=O)=O
Biological Activity: Atazanavir-d18 is the d18 labled Atazanavir (HY-17367). Atazanavir is a selective HIV-1 protease inhibitor[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Atazanavir-d18 | Atazanavir-d18 is the d18 labled Atazanavir (HY-17367). Atazanavir is a selective HIV-1 protease inhibitor. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Atazanavir (Standard) | ≥98% | Atazanavir (Standard) is the analytical standard of Atazanavir. This product is intended for research and analytical applications. Atazanavir (BMS-232632) is a highly selective and orally active HIV-1 protease inhibitor . Atazanavir is a substrate and inhibitor of CYP3A4, and an inhibitor of P-glycoprotein (P-gp). Atazanavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 3.49 μM. Atazanavir inhibits cardiac fibrosis, hyperlipidemia and induces malignant glioma death. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Atazanavir-d6 | 99.28% | Atazanavir-d6 is deuterium labeled Atazanavir. Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration. Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp). Atazanavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 3.49 μM. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Atazanavir-d5 | Atazanavir-d5 is the deuterium labeled Atazanavir. Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration. Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp). Atazanavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 3.49 μM. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Atazanavir-d15 | Atazanavir-d15 is the d15 labled Atazanavir (HY-17367). Atazanavir is a selective HIV-1 protease inhibitor. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Atazanavir-d9 | Atazanavir-d9 is the deuterium labeled Atazanavir. Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration. Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp). Atazanavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 3.49 μM. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Atazanavir-d24 | Atazanavir-d24 (BMS-232632-d24) is deuterium labeled Atazanavir. Atazanavir (BMS-232632) is a highly selective and orally active HIV-1 protease inhibitor . Atazanavir is a substrate and inhibitor of CYP3A4, and an inhibitor of P-glycoprotein (P-gp). Atazanavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 3.49 μM. Atazanavir inhibits cardiac fibrosis, hyperlipidemia and induces malignant glioma death. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Atazanavir | 99.13% | Atazanavir (BMS-232632) is a highly selective and orally active HIV-1 protease inhibitor . Atazanavir is a substrate and inhibitor of CYP3A4, and an inhibitor of P-glycoprotein (P-gp). Atazanavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 3.49 μM. Atazanavir inhibits cardiac fibrosis, hyperlipidemia and induces malignant glioma death. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
